-
1.发明申请公开(公告)号：US20180002435A1
公开(公告)日：2018-01-04
申请号：US15546630
申请日：2016-01-25
发明人： Barbara Johnson SASU , Arvind RAJPAL , Philippe DUCHATEAU , Alexandre JUILLERAT , Julien VALTON
IPC分类号： C07K16/28 , C07K14/705 , G01N15/10 , G01N15/14 , C12N5/0783 , C07K14/725 , G01N15/00
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.
-
公开(公告)号：US20180002427A1
公开(公告)日：2018-01-04
申请号：US15546619
申请日：2016-01-25
申请人： CELLECTIS
发明人： Julianne SMITH , Julien VALTON , Philippe DUCHATEAU , Alexandre JUILLERAT , Arvind RAJPAL , Barbra Johnson SASU
IPC分类号： C07K16/28 , C12N5/00 , C07K16/30 , A61K39/00 , A61K35/17 , C12N5/0783 , C07K14/725
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CLL1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CLL1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.
-
公开(公告)号：US20200237823A1
公开(公告)日：2020-07-30
申请号：US16755082
申请日：2018-03-09
申请人： CELLECTIS
摘要： The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
-
4.发明申请公开(公告)号：US20190328783A1
公开(公告)日：2019-10-31
申请号：US16092414
申请日：2017-04-13
申请人： CELLECTIS
IPC分类号： A61K35/17 , C07K14/725 , C12N5/0783 , C12N15/85
摘要： The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering prodrug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific prodrug in case of occurrence of a serious adverse event. The invention opens the way to safer and tunable adoptive immunotherapy strategies for treating cancer.
-
5.发明申请公开(公告)号：US20190151478A1
公开(公告)日：2019-05-23
申请号：US16092417
申请日：2017-04-13
申请人： CELLECTIS
摘要： The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering drug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific drug in case of occurrence of a serious adverse even. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.
-
6.发明申请公开(公告)号：US20180291343A1
公开(公告)日：2018-10-11
申请号：US15556558
申请日：2016-03-11
申请人： Cellectis
IPC分类号： C12N5/0783 , C07K16/28 , C07K14/705 , C12N15/11 , C12N9/22 , C07K14/74 , C07K14/005 , A61K35/17 , C12N5/00
摘要： The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.
-
公开(公告)号：US20180000914A1
公开(公告)日：2018-01-04
申请号：US15546604
申请日：2016-01-25
申请人： Cellectis
发明人： Julien VALTON , Philippe DUCHATEAU , Alexandre JUILLERAT , Arvind RAJPAL , Barbra Johnson SASU , Julianne SMITH
IPC分类号： A61K39/00 , C07K14/725 , C12N5/0783 , C07K14/735 , A61K39/395 , C07K16/28 , C07K14/705
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an anti-HSP70 monoclonal antibody, conferring specific immunity against HSP70 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating in particular leukemia.
-
公开(公告)号：US20240141293A1
公开(公告)日：2024-05-02
申请号：US18540309
申请日：2023-12-14
申请人： CELLECTIS
IPC分类号： C12N5/0783 , A61K35/17 , C12N9/22 , C12N15/90
CPC分类号： C12N5/0638 , A61K35/17 , C12N9/22 , C12N15/907 , C12N2510/00 , C12N2750/14143 , C12N2830/008
摘要： The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
-
公开(公告)号：US20200224163A1
公开(公告)日：2020-07-16
申请号：US16340222
申请日：2017-10-19
申请人： CELLECTIS
IPC分类号： C12N5/0783 , A61K35/17 , C12N15/90 , C12N9/22
摘要： The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
-
10.发明申请公开(公告)号：US20180171298A1
公开(公告)日：2018-06-21
申请号：US15578946
申请日：2016-06-30
申请人： Cellectis
IPC分类号： C12N5/0783 , C12N15/63 , A61K35/17 , A61K45/06 , C12N9/22 , C07K14/47 , C07K14/725 , C12N9/12
CPC分类号： C12N5/0646 , A61K35/17 , A61K45/06 , A61K2039/515 , A61K2039/572 , C07K14/4703 , C07K14/7051 , C12N9/12 , C12N9/22 , C12N15/63 , C12N2510/00
摘要： The present invention relates to methods for improving therapeutic activity of NK cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as TAL-nuclease, CRISPR or Argonaute. An additional genetic modification can be performed by (over)expressing at least one gene involved in N K function. The present invention encompasses also engineered NK cell, pharmaceutical composition containing the same.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.029 秒)
